

ADDITIONAL MATERIAL

Table 1 of the supplementary data. Missing data

Variable	Missing, No.	%
<i>Recipient</i>		
Age	0	0.00
Sex	0	0.00
Weight	63	1.70
Etiology	0	0.00
Renal dysfunction (creatinine > 2 mg/dL or dialysis)	187	5.05
Estimated glomerular filtration rate	995	26.87
Pulmonary vascular resistance	485	13.10
Serum bilirubin > 2 mg/dL	361	9.75
Bilirubin, mg/dL	1395	37.67
Infection	146	3.94
Diabetes	155	4.19
Respiratory disease	217	5.86
Cytomegalovirus serology	236	6.37
Peripheral vascular disease	168	4.54
Mechanical ventilation	156	4.21
Pretransplant circulatory support	139	3.75
Previous sternotomy	165	4.46
Malignancy	182	4.91
Left ventricular ejection fraction	300	8.10
Amiodarone prior to transplant	275	7.43
<i>Donor</i>		
Age	50	1.35
Sex	80	2.16
Weight	117	3.16
Cytomegalovirus serology	721	19.47
Cardiac arrest	1238	33.43
Cause of death	56	1.51
<i>Procedure</i>		
Cold ischemia time	57	1.54
Surgical technique	90	2.43
Immunosuppressive induction	185	5.00
High priority (urgent)	23	0.62
Transplant era	0	0.00
<i>Donor-recipient interaction</i>		
Donor-recipient weight ratio	159	4.29
Donor-recipient sex mismatch	80	2.16
Cytomegalovirus serology mismatch	809	21.85

Table 2 of the supplementary data. Cox regression analysis for 1-year mortality

	Univariate			Multivariable		
	HR	95%CI	P	HR	95%CI	P
Recipient						
Age, y	1.008	1.002-1.014	.010	1.016	1.009-1.023	<.001
Sex, female	1.053	0.897-0.238	.530			
Weight, kg	0.999	1.993-1.004	.667			
Positive cytomegalovirus serology	1.028	0.850-1.244	.772			
Renal dysfunction	1.531	1.289-1.819	<.001	1.363	1.140-1.623	.001
PVR, Wood units	1.049	1.023-1.075	<.001	1.041	1.011-1.071	.008
Bilirubin > 2 mg/dL	1.428	1.191-1.714	<.001	1.280	1.058-1.550	.011
Diabetes	1.161	0.945-1.424	.153			
Respiratory disease	1.048	0.825-1.330	.701			
Peripheral artery disease	1.345	0.908-1.992	.140			
Infection	1.578	1.266-1.967	<.001	1.196	0.937-1.525	.151
Mechanical ventilation	2.367	1.911-2.933	<.001	1.939	1.486-2.530	<.001
Circulatory support prior to HT			<.001			
No	1	-		1	-	
IABP	1.654	1.334-2.051	<.001	1.214	0.889-1.658	.222
ECMO	1.725	1.201-2.477	.003	1.235	0.780-1.955	.368
Ventricular assistance device	1.204	0.917-1.581	.182	0.804	0.503-1.285	.362
Prior sternotomy	1.384	1.130-1.694	.002	1.592	1.183-2.143	.002
Malignancy	1.298	0.959-1.758	.091	1.371	1.010-1.862	.043
LVEF, %	1.003	0.996-1.009	.417			
Amiodarone prior to HT	1.123	0.948-1.332	.180			
Etiology of the underlying heart disease			<.001			
Dilated	1	-		1	-	
Hypertrophic	1.104	0.862-1.413	.435	1.378	1.067-1.781	.014
Restrictive	1.332	1.031-1.720	.028	1.484	1.141-1.930	.003
Donor						
Age, y	1.003	0.998-1.008	.288			
Sex, female	1.145	0.985-1.331	.077	1.244	1.066-1.451	.006
Weight, kg	0.999	0.993-1.004	.644			
Positive cytomegalovirus serology	0.961	0.798-1.155	.664			
Cause of death			.260			
Cranial trauma	1	-				
Traffic accident	1.051	0.812-1.362	.704			
Stroke	1.277	1.011-1.613	.040			
Cranial hemorrhage	1.126	0.929-1.364	.225			
Cerebral anoxia	0.773	0.463-1.291	.325			
Others	1.098	0.834-1.447	.505			
Recipient-donor interaction						
Recipient/donor weight	0.993	0.670-1.471	.971			
Recipient male/donor female	1.130	0.948-1.347	.173			
Surgical procedure						

González-Urbistondo, F *et al.* Prognosis after heart transplant in patients with hypertrophic and restrictive cardiomyopathy. A nationwide registry analysis. *Rev Esp Cardiol.* 2023.

<i>High priority, urgent</i>	1.549	1.330-1.804	<.001	1.161	0.904-1.491	.243
<i>Cold ischemia time, min.</i>	1.001	1.000-1.002	.020	1.001	0.999-1.002	.075
<i>Surgical technique, bicaval</i>	0.911	0.787-1.055	.213			
<i>Period</i>			<.001			
1984-1991	1	-		1	-	
1992-2001	0.642	0.499-0.827	.001	0.570	0.435-0.747	<.001
2002-2011	0.749	0.583-0.963	.024	0.738	0.539-1.012	.060
2012-2021	0.537	0.415-0.694	<.001	0.516	0.365-0.729	<.001
Immunosuppressive induction			<.001			
<i>No</i>	1	-		1	-	
<i>ATG/ALT</i>	0.716	0.556-0.921	.009	0.749	0.573-0.980	.035
<i>OKT3</i>	0.443	0.352-0.556	<.001	0.507	0.392-0.656	<.001
<i>Anti-CD25</i>	0.412	0.344-0.494	<.001	0.357	0.289-0.440	<.001
<i>Others</i>	0.663	0.393-1.119	.124	0.517	0.302-0.885	.016

95%CI, 95% confidence interval; ATG/ALT, Antithymocyte globuline/antilymphocytic therapy; Anti-CD25, basiliximab or daclizumab; ECMO, extracorporeal membrane oxygenation; HR, hazard ratio; HT, heart transplantation; IABP, intra-aortic balloon pulsation; LVEF, left ventricular ejection fraction; PVR, pulmonary vascular resistance.

Table 3 of the supplementary data. Cox regression analysis for 5-year mortality

	Univariate			Multivariable		
	HR	95%CI	P	HR	95%CI	P
Recipient						
Age, y	1.007	1.002-1.012	.005	1.015	1.009-1.020	<.001
Sex, female	0.958	0.835-1.098	.534			
Weight, kg	1.000	0.996-1.005	.983			
Positive cytomegalovirus serology	1.063	0.911-1.241	.436			
Renal dysfunction	1.359	1.172-1.576	<.001	1.285	1.102-1.498	.001
PVR, Wood units	1.041	1.017-1.066	.001	1.028	1.000-1.056	.052
Bilirubin > 2 mg/dL	1.311	1.128-1.524	<.001	1.190	1.016-1.393	.031
Diabetes	1.149	0.969-1.362	.110			
Respiratory disease	1.152	0.952-1.394	.147			
Peripheral artery disease	1.197	0.840-1.705	.320			
Infection	1.490	1.235-1.797	<.001	1.243	1.012-1.527	.038
Mechanical ventilation	2.040	1.687-2.467	<.001	1.722	1.366-2.170	<.001
Circulatory support prior to HT			.001			
No	1	-		1	-	
IABP	1.406	1.163-1.700	<.001	0.987	0.760-1.281	.920
ECMO	1.433	1.035-1.984	.030	1.108	0.744-1.652	.613
Ventricular assistance device	1.061	0.839-1.342	.619	0.782	0.526-1.163	.225
Prior sternotomy	1.225	1.028-1.460	.023	1.444	1.123-1.857	.004
Malignancy	1.336	1.039-1.718	.024	1.457	1.132-1.875	.003
LVEF, %	1.000	0.994-1.005	.873			
Amiodarone prior to HT	1.026	0.888-1.185	.729			
Etiology of the underlying heart disease			.02			
Dilated	1	-		1	-	
Hypertrophic	0.894	0.716-1.116	.332	1.172	0.931-1.474	.176
Restrictive	1.307	1.055-1.618	.014	1.518	1.221-1.888	<.001
Donor						
Age, y	1.001	0.997-1.005	.624			
Sex, female	1.039	0.915-1.179	.556			
Weight, kg	0.999	0.994-1.003	.623			
Positive cytomegalovirus serology	1.008	0.863-1.177	.923			
Cause of death			.118			
Craneal trauma	1	-				
Traffic accident	0.878	0.706-1.092	.242			
Stroke	1.177	0.973-1.423	.093			
Craneal hemorrhage	0.964	0.824-1.127	.644			
Cerebral anoxia	0.777	0.520-1.161	.219			
Others	0.967	0.770-1.214	.770			
Recipient-donor interaction						
Recipient/donor weight	1.078	0.781-1.489	.648			
Recipient male/donor female	1.097	0.946-1.272	.219			
Surgical procedure						

González-Urbistondo, F *et al.* Prognosis after heart transplant in patients with hypertrophic and restrictive cardiomyopathy. A nationwide registry analysis. *Rev Esp Cardiol.* 2023.

<i>High priority (urgent)</i>	1.431	1.258-1.628	<.001	1.297	1.058-1.591	.012
<i>Cold ischemia time, min</i>	1.001	1.000-1.002	.217			
<i>Surgical technique (bicaval)</i>	0.842	0.746-0.950	.005	0.916	0.802-1.045	.192
<i>Period</i>			<.001			
1984-1991	1	-		1	-	
1992-2001	0.759	0.612-0.940	.012	0.712	0.567-0.892	.003
2002-2011	0.794	0.640-0.985	.036	0.820	0.624-1.078	.155
2012-2021	0.513	0.410-0.641	<.001	0.512	0.377-0.696	<.001
Immunosuppressive induction			<.001			
<i>No</i>	1	-		1	-	
<i>ATG/ALT</i>	0.788	0.636-0.976	.029	0.769	0.614-0.964	.023
<i>OKT3</i>	0.617	0.514-0.742	<.001	0.623	0.508-0.764	<.001
<i>Anti-CD25</i>	0.497	0.426-0.581	<.001	0.488	0.405-0.588	<.001
<i>Others</i>	0.750	0.480-1.170	.205	0.597	0.377-0.946	.028

95%CI, 95% confidence interval; ATG/ALT, antithymocyte globuline/antilymphocytic therapy; anti-CD25, basiliximab or daclizumab; ECMO, extracorporeal membrane oxygenation; HR, hazard ratio; HT, heart transplant; IABP, intra-aortic balloon pulsation; LVEF, left ventricular ejection fraction; PVR, pulmonary vascular resistance.

Table 4 of the supplementary data. Multivariable adjusted 1-year and 5-year mortality risks according to the etiology of the underlying heart disease

		1-year mortality		
		Dilated, HR (95%CI)	Hypertrophic, HR (95%CI)	Restrictive, HR (95%CI)
Reference group	Dilated		1.38 (1.07-1.78) <i>P</i> = .01	1.48 (1.14-1.93) <i>P</i> = .003
	Hypertrophic	0.73 (0.56-0.94) <i>P</i> = .01		1.08 (0.76-1.52) <i>P</i> = .67
	Restrictive	0.67 (0.52-0.88) <i>P</i> = .003	0.93 (0.66-1.31) <i>P</i> = .67	
		5-year mortality		
		Dilated, HR (95%CI)	Hypertrophic, HR (95%CI)	Restrictive, HR (95%CI)
Reference group	Dilated		1.17 (0.93-1.47) <i>P</i> = .18	1.52 (1.22-1.89) <i>P</i> < .001
	Hypertrophic	0.85 (0.68-1.07) <i>P</i> = .18		1.30 (0.96-1.75) <i>P</i> = .09
	Restrictive	0.66 (0.53-0.82) <i>P</i> < .001	0.77 (0.57-1.04) <i>P</i> = .09	

95%CI, 95% confidence interval; HR, hazard ratio.

González-Urbistondo, F *et al.* Prognosis after heart transplant in patients with hypertrophic and restrictive cardiomyopathy. A nationwide registry analysis. *Rev Esp Cardiol.* 2023.

Table 5 of the supplementary data. Results of the multivariable adjusted models after exclusion of the variable high priority (urgent) transplantation from the full adjusted models

		1-year mortality HR (95%CI)	5-year mortality HR (95%CI)
Hypertrophic vs dilated	Full model	1.38 (1.07-1.78)	1.17 (0.93-1.47)
	W/o urgent	1.37 (1.06-1.77)	1.16 (0.93-1.47)
Restrictive vs dilated	Full model	1.48 (1.14-1.93)	1.52 (1.22-1.89)
	W/o urgent	1.49 (1.15-1.94)	1.53 (1.23-1.90)
Hypertrophic vs restrictive	Full model	0.93 (0.66-1.31)	0.77 (0.57-1.04)
	W/o urgent	0.94 (0.67-1.32)	0.76 (0.57-1.03)

95%CI, 95% confidence interval; HR, hazard ratio.

Table 6 of the supplementary data. Characteristics of the population according to the etiology of restrictive cardiomyopathy

	Nonamyloidosis (n = 170)	Amyloidosis (n = 60)	
Recipient			
<i>Age, y</i>	46.5 [21.0]	54.5 [17.0]	< .001
<i>Sex, female</i>	89 (52.4)	36 (40.0)	.06
<i>Weight, kg</i>	62.0 [18.0]	67.5 [15.0]	.03
<i>Positive cytomegalovirus serology</i>	126 (78.3)	75 (83.3)	.34
<i>Renal dysfunction</i>	34 (21.1)	21 (23.9)	.62
<i>PVR, Wood units</i>	1.84 [1.59]	1.71 [1.25]	.36
<i>Bilirubin > 2 mg/dL</i>	33 (20.9)	12 (13.6)	.16
<i>Diabetes</i>	15 (9.3)	4 (4.5)	.17
<i>Respiratory disease</i>	10 (6.3)	7 (7.8)	.66
<i>Peripheral artery disease</i>	6 (3.6)	0 (0.0)	.07
<i>Infection</i>	10 (6.1)	3 (3.3)	.33
<i>Mechanical ventilation</i>	13 (7.9)	5 (5.6)	.49
<i>Circulatory support prior to HT</i>			.91
No	139 (83.7)	77 (85.6)	
IABP	13 (7.8)	5 (5.6)	
ECMO	6 (3.6)	3 (3.3)	
Ventricular assistance	8 (4.8)	5 (5.6)	
<i>Prior sternotomy</i>	21 (12.7)	5 (5.7)	.08
<i>Malignancy</i>	12 (7.4)	10 (11.5)	.28
<i>LVEF, %</i>	40.0 [28.0]	40.0 [17.0]	.79
<i>Amiodarone prior to HT</i>	35 (22.6)	8 (9.4)	.01
Donor			
<i>Age, y</i>	42.0 [24.0]	43.0 [22.0]	.16
<i>Sex, female</i>	82 (48.8)	44 (49.4)	.92
<i>Weight, kg</i>	70.0 [15.0]	70.0 [19.0]	.10
<i>Positive cytomegalovirus serology</i>	106 (73.1)	64 (76.2)	.61
<i>Cause of death</i>			.50
Craneal trauma	34 (20.1)	10 (11.1)	
Traffic accident	17 (10.1)	9 (10.0)	
Stroke	23 (13.6)	15 (16.7)	
Craneal hemorrhage	72 (42.6)	40 (44.4)	
Cerebral anoxia	5 (3.0)	5 (5.6)	
Others	18 (10.7)	11 (12.2)	
Recipient-donor interaction			
<i>Recipient/donor weight</i>	0.93 [0.26]	0.93 [0.29]	.66
<i>Recipient male/donor female</i>	28 (16.7)	17 (19.1)	
Surgical procedure			
<i>High priority, urgent</i>	43 (25.3)	17 (18.9)	.24
<i>Cold ischemia time, min</i>	190.0 [105.0]	199.0 [90.0]	.90
<i>Surgical technique, bicaval</i>	82 (48.5)	27 (30.3)	.005
<i>Period</i>	10 (5.9)	2 (2.2)	.12

González-Urbistondo, F *et al.* Prognosis after heart transplant in patients with hypertrophic and restrictive cardiomyopathy. A nationwide registry analysis. *Rev Esp Cardiol.* 2023.

1984-1991			
1992-2001	32 (18.8)	9 (10.0)	
2002-2011	58 (34.1)	35 (38.9)	
2012-2021	70 (41.2)	44 (48.9)	
Immunosuppressive induction			.09
<i>No</i>	28 (17.4)	15 (16.7)	
<i>ATG/ALT</i>	9 (5.6)	4 (4.4)	
<i>OKT3</i>	24 (14.9)	4 (4.4)	
<i>Anti-CD25</i>	96 (59.6)	66 (73.3)	
<i>Others</i>	4 (2.5)	1 (1.1)	

ATG/ALT, antithymocyte globuline/antilymphocytic therapy; anti-CD25, basiliximab or daclizumab; ECMO, extracorporeal membrane oxygenation; HT, heart transplant; IABP, intra-aortic balloon pulsation; LVEF, left ventricular ejection fraction; PVR, pulmonary vascular resistance.

Table 7 of the supplementary data. Cox regression analysis for 5-year mortality in recipients with restrictive cardiomyopathy

	Univariate			Multivariable		
	HR	95%CI	P	HR	95%CI	P
Recipient						
<i>Amyloidosis vs nonamyloidosis</i>	1.623	1.078-2.444	.02	1.844	1.178-2.889	.007
<i>Age, y</i>	1.005	0.988-1.022	.61			
<i>Sex, female</i>	1.080	0.719-1.621	.712			
<i>Weight, kg</i>	0.999	0.984-1.016	.999			
<i>Positive cytomegalovirus serology</i>	0.902	0.547-1.487	.685			
<i>Renal dysfunction</i>	1.255	0.758-1.981	.407			
<i>PVR, Wood units</i>	1.114	0.985-1.260	.085	1.087	0.945-1.251	.243
<i>Bilirubin > 2 mg/dL</i>	1.083	0.626-1.872	.776			
<i>Diabetes</i>	1.405	0.702-2.813	.337			
<i>Respiratory disease</i>	1.781	0.922-3.437	.086	2.041	1.001-4.162	.050
<i>Peripheral artery disease</i>	0.504	0.071-3.576	.493			
<i>Infection</i>	1.792	0.848-3.788	.126			
<i>Mechanical ventilation</i>	2.574	1.396-4.746	.002	1.954	0.965-3.957	.063
<i>Circulatory support prior to HT</i>			.453			
No	1					
IABP	0.922	0.403-2.111	.848			
ECMO	2.066	0.839-5.086	.114			
Ventricular assistance device	0.926	0.339-2.530	.881			
<i>Prior sternotomy</i>	1.048	0.527-2.084	.894			
<i>Malignancy</i>	1.788	1.975-3.276	.060	2.125	1.074-4.206	.030
<i>LVEF, %</i>	1.002	0.989-1.015	.803			
<i>Amiodarone prior to HT</i>	0.848	0.539-1.336	.478			
Donor						
<i>Age, y</i>	0.994	0.980-1.008	.379			
<i>Sex, female</i>	1.078	0.718-1.620	.717			
<i>Weight, kg</i>	0.994	0.978-1.011	.505			
<i>Positive cytomegalovirus serology</i>	0.972	0.589-1.605	.912			
<i>Cause of death</i>			.338			
Craneal trauma	1	-				
Traffic accident	1.148	0.553-2.383	.711			
Stroke	1.023	0.522-2.004	.948			
Craneal hemorrhage	0.612	0.342-1.096	.098			
Cerebral anoxia	0.922	0.312-2.723	.883			
Others	0.993	0.478-2.061	.984			
Recipient-donor interaction						
<i>Recipient/donor weight</i>	1.241	0.445-3.457	.680			
<i>Recipient male/donor female</i>	0.954	0.556-1.637	.864			
Surgical procedure						
<i>High priority, urgent</i>	1.346	0.851-2.128	.205			
<i>Cold ischemia time, min</i>	1.004	1.001-1.009	.012	1.004	1.000-1.008	.045

González-Urbistondo, F *et al.* Prognosis after heart transplant in patients with hypertrophic and restrictive cardiomyopathy. A nationwide registry analysis. *Rev Esp Cardiol.* 2023.

<i>Surgical technique, bicaval</i>	0.689	0.458-1.036	.074	0.815	0.510-1.301	.391
<i>Period</i>			.064			
<i>1984-1991</i>	1			1		
1992-2001	0.115	0.373-3.336	.845	1.147	0.303-4.341	.840
2002-2011	1.467	0.526-4.093	.464	2.548	0.555-11.701	.229
2012-2021	0.777	0.274-2.201	.634	1.472	0.306-7.087	.306
Immunosuppressive induction			<.001			
<i>No</i>	1	-		1		
<i>ATG/ALT</i>	0.162	0.038-1.681	.094	0.200	0.046-0.870	.032
<i>OKT3</i>	0.520	0.259-1.044	.066	0.827	0.316-2.165	.698
<i>Anti-CD25</i>	0.370	0.227-0.603	<.001	0.281	0.161-0.490	<.001
<i>Others</i>	1.428	0.492-4.150	.512	0.669	0.207-2.162	.502

95%CI, 95% confidence interval; ATG/ALT, antithymocyte globuline/antilymphocytic therapy; anti-CD25, basiliximab or daclizumab; ECMO, extracorporeal membrane oxygenation; HR, hazard ratio; HT, heart transplant; IABP, intra-aortic balloon pulsation; LVEF, left ventricular ejection fraction; PVR, pulmonary vascular resistance.

Table 8 of the supplementary data. Cox regression analysis for 5-year mortality in recipients with hypertrophic cardiomyopathy

	Univariate			Multivariable		
	HR	95%CI	P	HR	95%CI	P
Recipient						
<i>Left ventricular ejection fraction \geq 50%</i>	0.830	0.497-1.387	.478	1.219	0.698-2.127	.486
<i>Age, y</i>	1.022	1.004-1.041	.017	1.034	1.014-1.056	.001
<i>Sex, female</i>	1.157	0.756-1.770	.502			
<i>Weight, kg</i>	0.990	0.975-1.006	.219			
<i>Positive cytomegalovirus serology</i>	1.592	0.921-2.753	.096	1.255	0.712-2.212	.433
<i>Renal dysfunction</i>	1.041	0.604-2.793	.886			
<i>PVR, Wood units</i>	1.150	1.029-1.286	.014	1.156	1.019-1.311	.020
<i>Bilirubin > 2 mg/dL</i>	1.359	0.775-2.384	.285			
<i>Diabetes</i>	0.523	0.212-1.295	.161			
<i>Respiratory disease</i>	1.880	0.971-3.639	.061	1.490	0.739-3.003	.265
<i>Peripheral vascular disease</i>	1.774	0.434-7.253	.425			
<i>Infection</i>	1.287	0.593-2.790	.523			
<i>Mechanical ventilation</i>	3.607	1.656-7.855	.001	5.049	1.894-13.457	.001
<i>Circulatory support prior to HT</i>			.224			
No	1					
IABP	1.308	0.567-3.016	.766			
ECMO	2.235	0.449-23.317	.244			
Ventricular assistance device	1.799	0.926-3.496	.083			
<i>Prior sternotomy</i>	1.693	1.002-2.859	.049	1.426	0.773-2.630	.255
<i>Malignancy</i>	1.214	0.384-3.844	.741			
<i>LVEF, %</i>	0.995	0.982-1.009	.483			
<i>Amiodarone prior to HT</i>	0.986	0.602-1.614	.954			
Donor						
<i>Age, y</i>	1.007	0.992-1.023	.358			
<i>Sex, female</i>	1.013	0.657-1.562	.954			
<i>Weight, kg</i>	0.995	0.979-1.010	.483			
<i>Positive cytomegalovirus serology</i>	1.176	0.681-2.030	.561			
<i>Cause of death</i>			.487			
Craneal trauma	1	-				
Traffic accident	0.635	0.237-1.699	.365			
Stroke	1.145	0.600-2.198	.676			
Craneal hemorrhage	0.840	0.484-1.458	.535			
Cerebral anoxia	0.848	0.290-2.482	.764			
Others	0.443	0.167-1.176	.102			
Recipient-donor interaction						
<i>Recipient/donor weight</i>	0.742	0.200-2.752	.655			
<i>Recipient male/donor female</i>	0.898	0.478-1.687	.738			
Surgical procedure						

González-Urbistondo, F *et al.* Prognosis after heart transplant in patients with hypertrophic and restrictive cardiomyopathy. A nationwide registry analysis. *Rev Esp Cardiol.* 2023.

<i>High priority, urgent</i>	1.548	0.953-2.515	.078	1.309	0.672-2.547	.429
<i>Cold ischemic time,min</i>	1.001	0.998-1.004	.564			
<i>Surgical technique, bicaval</i>	0.833	0.543-1.278	.404			
<i>Period</i>			.011			
1984-1991	1					
1992-2001	1.066	0.396-2.870	.900	1.483	0.496-4.431	.481
2002-2011	0.680	0.260-1.775	.430	0.978	0.332-2.883	.967
2012-2021	0.436	0.171-1.109	.081	0.586	0.196-1.753	.339
Immunosuppressive induction			<.001			
<i>No</i>	1	-		1	-	
<i>ATG/ALT</i>	0.902	0.441-1.843	.777	0.964	0.443-2.099	.926
<i>OKT3</i>	0.563	0.253-1.254	.160	0.335	0.120-0.930	.036
<i>Anti-CD25</i>	0.338	0.203-0.564	<.001	0.350	0.194-0.630	<0.001
<i>Others</i>	0.358	0.048-2.642	.314	0.179	0.023-1.462	.108

95%CI, 95% confidence interval; ATG/ALT, antithymocyte globuline/antilymphocytic therapy; anti-CD25, basiliximab or daclizumab; ECMO, extracorporeal membrane oxygenation; HR, hazard ratio; HT, heart transplant; IABP, intra-aortic balloon pulsation; LVEF, left ventricular ejection fraction; PVR, pulmonary vascular resistance.